Best Practice & Research Clinical Obstetrics & Gynaecology
Volume 24, Issue 1 , Pages 29-38 , February 2010

The use of hormonal contraception and its protective role against endometrial and ovarian cancer

References 

  1. Cogliano V, Grosse Y, Baan R, et al. Carcinogeneity of combined oestrogen-progestagen contraceptives and menopausal treatment. Lancet Oncol. 2005;6:552–553
  2. Franco EL, Duarte-Franco E. Ovarian cancer and oral contraceptives. Lancet. 2008;371:277–278
  3. Editorial. The case for preventing ovarian cancer. Lancet. 2008;371:275
  4. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23257 women with ovarian cancer and 87303 controls. Lancet. 2008;371:303–314
  5. Schlesselman JJ. Risk of endometrial cancer in relation to use of combined oral contraceptives. A practitioner's guide to meta-analysis. Hum Reprod. 1997;12:1851–1863
  6. Vessey M, Painter R. Oral contraceptive use and cancer. Findings in a large cohort study, 1968-2004. Br J Cancer. 2006;95:385–389
  7. Hannaford PC, Selvaraj S, Elliott AM, et al. Cancer risk among users of oral contraceptives: cohort data from the Royal College of General Practitioner's oral contraception study. BMJ. 2007;335:651–658
  8. Vessey MP, Painter R. Endometrial and ovarian cancer and oral contraceptives-findings in a large cohort study. Br J Cancer. 1995;71:1340–1342
  9. La Vecchia C. Oral contraceptives and ovarian cancer: an update. Eur J Cancer Prev. 2006;15:117–124
  10. Narod SA, Risch H, Moslehi R, et al. Oral contraceptives and the risk of hereditary ovarian cancer. N Eng J Med. 1998;339:424–428
  11. McGuire V, Felberg A, Mills M, et al. Relation of contraceptive and reproductive history to ovarian cancer risk in carriers and non-carriers of BRCA1 gene mutations. Am J Epidemiol. 2004;160:613–618
  12. Whittemore AS, Balise RR, Pharoah PD, et al. Oral contraceptive use and ovarian cancer risk among carriers of BRCA1 and BRCA2 mutations. Br J Cancer. 2004;91:1911–1915
  13. Modan B, Hartge P, Hirsh-Yechezkel G, et al. Parity, oral contraceptives andthe risk of ovarian cancer among carriers and non-carriers of a BRCA1 and BRCA2 mutation. N Eng J Med. 2001;345:235–240
  14. Ness RB, Grisso JA, Klapper J, et al. Risk of ovarian cancer in relation to estrogen and progestin dose and use characteristics of oral contraceptives. Am J Epidemiol. 2000;152:233–241
  15. Fathalla MF. Incessant ovulation-a factor in ovarian neoplasia?. ii Lancet. 1971;163
  16. CasagrandeJT Louie EW, Pike MC, et al. Incessant ovulation and ovarian cancer. ii Lancet. 1979;170–173
  17. Lowry S, Russell H, Hickey I, et al. Incessant ovulation and ovarian cancer. Lancet. 1991;337:1544–1545
  18. Godwin AK, Testa JR, Hamilton TC. The biology of ovarian cancer development. (Suppl) Cancer. 1993;71:530–536
  19. Tarlatzis BC, Grimbizis G, Bontis J, et al. Ovarian stimulation and ovarian tumours: a cretical reappraisal. Hum Reprod Update. 1995;3:284–301
  20. Grimbizis G, Tsalikis T, Tzioufa V, et al. Regression of endometrial hyperplasia after treatment with the gonadotrophin-releasing hormone analogue triptirelin: a prospective study. Hum Reprod. 1999;14:479–484
  21. Key TJ, Pike MC. The dose-effect relationship between "unopposed oestrogens and endometrial mitotic rate: its central role in explaining and predicting endometrial cancer risk. Br J Cancer. 1988;57:205–212

PII: S1521-6934(09)00115-1

doi: 10.1016/j.bpobgyn.2009.08.010

Best Practice & Research Clinical Obstetrics & Gynaecology
Volume 24, Issue 1 , Pages 29-38 , February 2010

Article Tools